130 related articles for article (PubMed ID: 9088592)
1. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
Baxter T; Eadie CJ
Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
Bonn R
Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
[TBL] [Abstract][Full Text] [Related]
3. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
4. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
Waller DG
J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
[TBL] [Abstract][Full Text] [Related]
5. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
6. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
Arthur RM; Mehmel H
Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
[TBL] [Abstract][Full Text] [Related]
8. Long-acting isosorbide mononitrate.
Prakash A; Markham A
Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
[TBL] [Abstract][Full Text] [Related]
9. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin.
Parker JD
J Cardiovasc Pharmacol; 1996 Nov; 28(5):631-8. PubMed ID: 8945675
[TBL] [Abstract][Full Text] [Related]
10. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
McClennen W; Hornestam B; Jonsson UE; Held P
Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
[TBL] [Abstract][Full Text] [Related]
11. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
[TBL] [Abstract][Full Text] [Related]
12. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
Yang LL; Yuan YS; Zhao FL
Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of nitrates.
Bogaert MG
Cardiovasc Drugs Ther; 1994 Oct; 8(5):693-9. PubMed ID: 7873466
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
16. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Sata H; Inoue K; Nii T; Kuroda T
Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
[TBL] [Abstract][Full Text] [Related]
17. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
Jähnchen E
Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
[TBL] [Abstract][Full Text] [Related]
18. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
[TBL] [Abstract][Full Text] [Related]
19. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara NS; Noble S
Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
[TBL] [Abstract][Full Text] [Related]
20. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris.
Thadani U; Bittar N
Am J Cardiol; 1992 Aug; 70(3):286-92. PubMed ID: 1632390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
